SG11202006259SA - Il-22 fc fusion proteins and methods of use - Google Patents

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Analytical Chemistry (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Water Supply & Treatment (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG11202006259SA2018-01-262019-01-25Il-22 fc fusion proteins and methods of useSG11202006259SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862622767P	2018-01-26	2018-01-26
PCT/US2019/015277WO2019148026A1 (en)	2018-01-26	2019-01-25	Il-22 fc fusion proteins and methods of use

Publications (1)

Publication Number	Publication Date
SG11202006259SAtrue SG11202006259SA (en)	2020-08-28

Family

ID=65441062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202006259SASG11202006259SA (en)	2018-01-26	2019-01-25	Il-22 fc fusion proteins and methods of use

Country Status (21)

Country	Link
US (1)	US20200362003A1 (en)
EP (1)	EP3743437A1 (en)
JP (1)	JP7349995B2 (en)
KR (1)	KR20200115546A (en)
CN (1)	CN111655717A (en)
AR (1)	AR114565A1 (en)
AU (1)	AU2019212709A1 (en)
BR (1)	BR112020013420A2 (en)
CA (1)	CA3087339A1 (en)
CL (2)	CL2020001944A1 (en)
CO (1)	CO2020009402A2 (en)
CR (1)	CR20200327A (en)
IL (1)	IL275742A (en)
MA (1)	MA51676A (en)
MX (1)	MX2020007018A (en)
PE (1)	PE20212075A1 (en)
PH (1)	PH12020551019A1 (en)
RU (1)	RU2020127792A (en)
SG (1)	SG11202006259SA (en)
TW (1)	TWI835772B (en)
WO (1)	WO2019148026A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109328069B (en)	2016-04-15	2023-09-01	亿一生物医药开发(上海)有限公司	Use of IL-22 in the treatment of necrotizing enterocolitis
WO2021021647A1 (en)*	2019-07-26	2021-02-04	Genentech, Inc.	Dosing for prevention or treatment of graft versus host disease (gvhd) with il-22 fc fusion proteins
EP3819307A1 (en)	2019-11-07	2021-05-12	CytoKi Pharma ApS	Therapeutic derivatives of interleukin-22
WO2021207662A1 (en)	2020-04-10	2021-10-14	Genentech, Inc.	Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2022073038A1 (en)*	2020-10-02	2022-04-07	Abbvie Inc.	Interleukin-22 (il-22) fusion proteins and uses thereof
IL302276A (en)	2020-10-23	2023-06-01	Asher Biotherapeutics Inc	Fusion with CD8 antigen binding molecules to modulate immune cell function
AU2021396247A1 (en)*	2020-12-09	2023-07-06	Asher Biotherapeutics, Inc.	Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
WO2023034758A1 (en)*	2021-08-30	2023-03-09	Cytoimmune Therapeutics, Inc.	Methods and compositions for cell expansion
CA3235508A1 (en)*	2021-10-19	2023-05-11	Soon Jae Park	Method for purifying fusion protein having igg fc domain
CN117603361A (en)*	2022-08-22	2024-02-27	复旦大学附属儿科医院	Fusion protein containing ANGPTL3 monoclonal antibody
EP4598584A1 (en)	2022-10-06	2025-08-13	Renexxion Ireland Limited	Compounds, compositions and methods for treating inflammatory bowel disease
KR20250095668A (en)*	2022-10-31	2025-06-26	삼성바이오에피스 주식회사	Method for removing impurities using affinity chromatography
WO2024130158A1 (en)*	2022-12-16	2024-06-20	Modernatx, Inc.	Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
WO2024197049A2 (en)*	2023-03-21	2024-09-26	The University Of Chicago	Methods and compositions comprising copolymers for the treatment of wounds

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS6023084B2 (en)	1979-07-11	1985-06-05	味の素株式会社	blood substitute
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en)	1980-03-24	1982-04-28	Genentech Inc	Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en)	1981-08-31	1986-03-14	Genentech Inc	Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
AU2353384A (en)	1983-01-19	1984-07-26	Genentech Inc.	Amplification in eukaryotic host cells
US4713339A (en)	1983-01-19	1987-12-15	Genentech, Inc.	Polycistronic expression vector construction
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hemoglobin combined with a poly(alkylene oxide)
EP0272253A4 (en)	1986-03-07	1990-02-05	Massachusetts Inst Technology	Method for enhancing glycoprotein stability.
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4717717A (en)	1986-11-05	1988-01-05	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5010182A (en)	1987-07-28	1991-04-23	Chiron Corporation	DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US5705485A (en)	1987-09-18	1998-01-06	Ethicon, Inc.	Gel formulations containing growth factors
US5457093A (en)	1987-09-18	1995-10-10	Ethicon, Inc.	Gel formulations containing growth factors
NZ226171A (en)	1987-09-18	1990-06-26	Ethicon Inc	Gel formulation containing polypeptide growth factor
GB8724885D0 (en)	1987-10-23	1987-11-25	Binns M M	Fowlpox virus promotors
JPH04501201A (en)	1987-12-21	1992-03-05	ジ・アップジョン・カンパニー	Agrobacterium-mediated transformation of germinated plant seeds
AU4005289A (en)	1988-08-25	1990-03-01	Smithkline Beecham Corporation	Recombinant saccharomyces
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
FR2646437B1 (en)	1989-04-28	1991-08-30	Transgene Sa	NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
US5130298A (en)	1989-05-16	1992-07-14	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US5206161A (en)	1991-02-01	1993-04-27	Genentech, Inc.	Human plasma carboxypeptidase B
US6407213B1 (en)	1991-06-14	2002-06-18	Genentech, Inc.	Method for making humanized antibodies
EP0604580A1 (en)	1991-09-19	1994-07-06	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JPH08511420A (en)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	Body
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
WO1998058964A1 (en)	1997-06-24	1998-12-30	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
DE69840412D1 (en)	1997-10-31	2009-02-12	Genentech Inc	METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
ES2292236T3 (en)	1998-04-02	2008-03-01	Genentech, Inc.	VARIATIONS OF ANTIBODIES AND THEIR FRAGMENTS.
WO1999054342A1 (en)	1998-04-20	1999-10-28	Pablo Umana	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DK1107791T3 (en)	1998-09-04	2007-09-03	Scios Inc	Hydrogel preparations for controlled release administration of growth factors
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
KR100797667B1 (en)	1999-10-04	2008-01-23	메디카고 인코포레이티드	How to regulate transcription of foreign genes
EP1229125A4 (en)	1999-10-19	2005-06-01	Kyowa Hakko Kogyo Kk	PROCESS FOR PRODUCING A POLYPEPTIDE
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
EA013563B1 (en)	2000-10-06	2010-06-30	Киова Хакко Кирин Ко., Лтд.	A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies
NZ592087A (en)	2001-08-03	2012-11-30	Roche Glycart Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
PL213948B1 (en)	2001-10-25	2013-05-31	Genentech Inc	Glycoprotein compositions
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
EP1502603A4 (en)	2002-04-09	2006-12-13	Kyowa Hakko Kogyo Kk	MEDICAMENT CONTAINING ANTIBODY COMPOSITION APPROPRIATE TO PATIENT SUFFERING FROM POLYMORPHISM FC gammma RIIIA
PL373256A1 (en)	2002-04-09	2005-08-22	Kyowa Hakko Kogyo Co, Ltd.	Cells with modified genome
AU2003236015A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition
JPWO2003085119A1 (en)	2002-04-09	2005-08-11	協和醗酵工業株式会社	Method for enhancing binding activity of antibody composition to Fcγ receptor IIIa
ES2362419T3 (en)	2002-04-09	2011-07-05	Kyowa Hakko Kirin Co., Ltd.	CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2301966A1 (en)	2002-12-16	2011-03-30	Genentech, Inc.	Immunoglobulin variants and uses thereof
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20080241884A1 (en)	2003-10-08	2008-10-02	Kenya Shitara	Fused Protein Composition
US20070134759A1 (en)	2003-10-09	2007-06-14	Harue Nishiya	Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
DE602004026470D1 (en)	2003-11-05	2010-05-20	Roche Glycart Ag	FC RECEPTOR AND EFFECTOR FUNCTION
JPWO2005053742A1 (en)	2003-12-04	2007-06-28	協和醗酵工業株式会社	Medicament containing antibody composition
PL1737891T3 (en)	2004-04-13	2013-08-30	Hoffmann La Roche	Anti-p-selectin antibodies
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
WO2006034488A2 (en)	2004-09-23	2006-03-30	Genentech, Inc.	Cysteine engineered antibodies and conjugates
JO3000B1 (en)	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
KR20080017362A (en)	2005-06-17	2008-02-26	제넨테크, 인크.	Use of vegf for wound healing
AR063975A1 (en)*	2006-11-28	2009-03-04	Centelion	FC FUSIONS WITH RECEIVER FOR FGF SOLUBLE MODIFIED WITH IMPROVED BIOLOGICAL ACTIVITY
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
MX346731B (en)	2010-04-23	2017-03-30	Genentech Inc *	Production of heteromultimeric proteins.
SG11201507429TA (en)*	2013-03-15	2015-10-29	Genentech Inc	Il-22 polypeptides and il-22 fc fusion proteins and methods of use

2019
- 2019-01-25SGSG11202006259SApatent/SG11202006259SA/enunknown
- 2019-01-25JPJP2020537767Apatent/JP7349995B2/enactiveActive
- 2019-01-25CACA3087339Apatent/CA3087339A1/enactivePending
- 2019-01-25WOPCT/US2019/015277patent/WO2019148026A1/ennot_activeCeased
- 2019-01-25BRBR112020013420-1Apatent/BR112020013420A2/enunknown
- 2019-01-25MXMX2020007018Apatent/MX2020007018A/enunknown
- 2019-01-25CNCN201980010357.9Apatent/CN111655717A/enactivePending
- 2019-01-25AUAU2019212709Apatent/AU2019212709A1/ennot_activeAbandoned
- 2019-01-25CRCR20200327Apatent/CR20200327A/enunknown
- 2019-01-25TWTW108102961Apatent/TWI835772B/enactive
- 2019-01-25MAMA051676Apatent/MA51676A/enunknown
- 2019-01-25EPEP19705616.1Apatent/EP3743437A1/enactivePending
- 2019-01-25ARARP190100177Apatent/AR114565A1/ennot_activeApplication Discontinuation
- 2019-01-25RURU2020127792Apatent/RU2020127792A/enunknown
- 2019-01-25KRKR1020207023986Apatent/KR20200115546A/ennot_activeCeased
- 2019-01-25PEPE2020000924Apatent/PE20212075A1/enunknown
2020
- 2020-06-29ILIL275742Apatent/IL275742A/enunknown
- 2020-06-29PHPH12020551019Apatent/PH12020551019A1/enunknown
- 2020-07-23CLCL2020001944Apatent/CL2020001944A1/enunknown
- 2020-07-24USUS16/938,696patent/US20200362003A1/enactivePending
- 2020-07-29COCONC2020/0009402Apatent/CO2020009402A2/enunknown
2021
- 2021-05-03CLCL2021001162Apatent/CL2021001162A1/enunknown

Also Published As

Publication number	Publication date
PH12020551019A1 (en)	2021-05-31
TWI835772B (en)	2024-03-21
MA51676A (en)	2021-05-05
PE20212075A1 (en)	2021-10-26
KR20200115546A (en)	2020-10-07
IL275742A (en)	2020-08-31
WO2019148026A8 (en)	2019-08-29
US20200362003A1 (en)	2020-11-19
WO2019148026A1 (en)	2019-08-01
JP2021511297A (en)	2021-05-06
JP7349995B2 (en)	2023-09-25
CL2021001162A1 (en)	2021-10-22
CR20200327A (en)	2020-11-05
MX2020007018A (en)	2020-09-07
AU2019212709A1 (en)	2020-08-13
CA3087339A1 (en)	2019-08-01
BR112020013420A2 (en)	2020-12-01
TW201938186A (en)	2019-10-01
AR114565A1 (en)	2020-09-23
EP3743437A1 (en)	2020-12-02
RU2020127792A (en)	2022-02-28
CL2020001944A1 (en)	2020-10-23
CN111655717A (en)	2020-09-11
CO2020009402A2 (en)	2020-08-10

Publication	Publication Date	Title
IL275742A (en)	2020-08-31	Il-22 fc fusion proteins and methods of use
IL288373A (en)	2022-01-01	Flt3l-fc fusion proteins and methods of use
IL280102A (en)	2021-03-01	Pd1-4-1bbl variant fusion protein and methods of use thereof
IL279510A (en)	2021-01-31	Progranulin-fc polypeptide fusion proteins and uses thereof
IL277288A (en)	2020-10-29	Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
DK3892628T3 (en)	2022-11-14	ULTRA-LONG-ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE
IL278090A (en)	2020-11-30	Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof
IL280103A (en)	2021-03-01	Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
ZA201506297B (en)	2018-11-28	Il-22 polypeptides and il-22 fc fusion proteins and methods of use
IL267861A (en)	2019-09-26	A pd1-41bbl fusion protein and methods of use thereof
PL3565828T3 (en)	2022-04-04	SIRP1 ALFA-41BBL fusion protein and methods of its use
DK4073098T5 (en)	2024-07-22	Ultra-long-acting insulin-Fc fusion proteins and methods of use
SG11202104912SA (en)	2021-06-29	Fusion protein and use thereof
SG11202110400QA (en)	2021-10-28	Fusion protein and use thereof
EP3999549A4 (en)	2023-07-12	Sialidase-pd-l1-antibody fusion proteins and methods of use thereof
EP3994179A4 (en)	2023-08-09	Sialidase-cd20-antibody fusion proteins and methods of use thereof
HK40050153A (en)	2021-12-24	Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
HK40049469A (en)	2021-12-17	Pd1-4-1bbl variant fusion protein and methods of use thereof
IL275602B (en)	2022-06-01	Il-22 polypeptides and il-22 fc fusion proteins and methods of use
HK40072937A (en)	2022-12-02	Sialidase-her2-antibody fusion proteins and methods of use thereof
HK40072868A (en)	2022-12-02	Flt3l-fc fusion proteins and methods of use
HK40036999A (en)	2021-06-04	Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
HK1261875A1 (en)	2020-01-03	Cd40l-fc fusion polypeptides and methods of use thereof
TH1501005499A (en)	2018-06-21	IL-22 polypeptide and IL-22 Fc fusion protein and how to use them

Movatterモバイル変換

SG11202006259SA - Il-22 fc fusion proteins and methods of use - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=65441062

Family Applications (1)

Country Status (21)

Families Citing this family (14)

Family Cites Families (80)

Also Published As

Similar Documents